New handbook on health economic assessments of medical devices

18 August 2022 - TLV carries out health economic assessments of medical technology products at the request of the Medical Technology ...

Read more →

TLV reconsiders Orkambi's subsidy

4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...

Read more →

TLV receives assignments for medicines for rare diseases

27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to analyse and make ...

Read more →

TLV receives a new assignment on precision medicine and ATMP

27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to continue the work ...

Read more →

Zeposia is included in the high-cost protection with limitation

17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022.  ...

Read more →

Givlaari is included in the high-cost protection with limitation

17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...

Read more →

Subsidy for medicine for Duchenne muscular dystrophy expires

16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...

Read more →

TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios

8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...

Read more →

TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors

2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...

Read more →

Health economic assessment of Trodelvy in advanced triple negative breast cancer

23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan).  ...

Read more →

TLV reconsiders subsidy of CGRP inhibitors

18 May 2022 - TLV has started a review of the CGRP inhibitors. ...

Read more →

Health economic assessment of Xevudy for the treatment of COVID-19

17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab).  ...

Read more →

Tepmetko is granted a temporary subsidy

16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...

Read more →

Health economic assessment of Abecma in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel).  ...

Read more →

Health economic assessment of Blenrep in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin).  ...

Read more →